Evidence map›Paper›PMID 40157130›Full record

ArticleEBioMedicine2025

Preclinical development of a replication-competent vesicular stomatitis virus-based Lassa virus vaccine candidate advanced into human clinical trials.

Christopher L Cooper, Gavin Morrow, Maoli Yuan, Thomas S Postler, Maxwell L Neal, Robert W Cross, Courtney Woolsey, Krystle N Agans, Viktoriya Borisevich, Ryan P McNamara and 28 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EBioMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Application of Orthoflavivirus Pseudovirus Technology in Antiviral Research.International journal of molecular sciences · 2026
    Review
  7. Robust polyfunctional CD8The Journal of general virology · 2025
    Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors.

Christopher L CooperIAVI, Vaccine Design and Development Laboratory, Jersey City, NJ 07302, USA.
Gavin MorrowIAVI, Vaccine Design and Development Laboratory, Jersey City, NJ 07302, USA.
Maoli YuanIAVI, Vaccine Design and Development Laboratory, Jersey City, NJ 07302, USA.
Thomas S PostlerIAVI, Vaccine Design and Development Laboratory, Jersey City, NJ 07302, USA.
Maxwell L NealCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA 98109, USA.
Robert W CrossGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77555, USA; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Courtney WoolseyGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77555, USA; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Krystle N AgansGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77555, USA; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Viktoriya BorisevichGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77555, USA; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Ryan P McNamaraRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard, Cambridge, MA 02139, USA.
Caroline AtyeoRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard, Cambridge, MA 02139, USA.
Vicky RoyRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard, Cambridge, MA 02139, USA.
Daritza GermosenRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard, Cambridge, MA 02139, USA.
Fuxiang HouIAVI, Vaccine Design and Development Laboratory, Jersey City, NJ 07302, USA.
Shui L LiIAVI, Vaccine Design and Development Laboratory, Jersey City, NJ 07302, USA.
Lucia ReiserovaIAVI, Vaccine Design and Development Laboratory, Jersey City, NJ 07302, USA.
Yesle ChoiIAVI, Vaccine Design and Development Laboratory, Jersey City, NJ 07302, USA.
Aaron WilsonIAVI, Vaccine Design and Development Laboratory, Jersey City, NJ 07302, USA.
Denise WagnerIAVI, Vaccine Design and Development Laboratory, Jersey City, NJ 07302, USA.
Olivia Wallace-SelmanIAVI, Vaccine Design and Development Laboratory, Jersey City, NJ 07302, USA.
Alexei CarpovIAVI, Vaccine Design and Development Laboratory, Jersey City, NJ 07302, USA.
Fuqiang GengIAVI, Vaccine Design and Development Laboratory, Jersey City, NJ 07302, USA.
Deborah J FrederickIAVI, Vaccine Design and Development Laboratory, Jersey City, NJ 07302, USA.
Joanne DeStefanoIAVI, Vaccine Design and Development Laboratory, Jersey City, NJ 07302, USA.
Anne M ErcoliniIAVI, Vaccine Design and Development Laboratory, Jersey City, NJ 07302, USA.
Adrian S EnriquezCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
Kathryn M HastieCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
Suzane Ramos da SilvaIAVI, Vaccine Design and Development Laboratory, Jersey City, NJ 07302, USA.
Eddy SayeedIAVI, New York, NY 10004, USA.
John W ColemanIAVI, Vaccine Design and Development Laboratory, Jersey City, NJ 07302, USA.
Andrew KilianskiIAVI, New York, NY 10004, USA.
Galit AlterRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard, Cambridge, MA 02139, USA.
Erica Ollmann SaphireCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
John D AitchisonCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA 98109, USA; Departments of Pediatrics and Biochemistry, University of Washington, Seattle, WA 98109, USA.
Thomas W GeisbertGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77555, USA; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Swati B GuptaIAVI, New York, NY 10004, USA.
Mark B FeinbergIAVI, New York, NY 10004, USA.
Christopher L ParksIAVI, Vaccine Design and Development Laboratory, Jersey City, NJ 07302, USA. Electronic address: cparks@iavi.org.

Funding

Specific and Broadly Active Monoclonal Antibody Therapeutics Against The FilovirusesU19AI142790 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI SAPHIRE, ERICA OLLMANN · 2019 to 2023
$40.0M
NIAID NIH HHS U19 AI142790
6 · The paper itself

Abstract

backgroundLassa fever (LF) is a zoonotic haemorrhagic disease caused by Lassa virus (LASV), which is endemic in West African countries. The multimammate rat is the main animal reservoir and its geographic range is expected to expand due to influences like climate change and land usage, and this will place larger parts of Africa at risk. We conducted preclinical development on a promising experimental vaccine that allowed its advancement into human trials.

methodsThe LF vaccine is based on a vesicular stomatitis virus (VSV) vector in which the VSV glycoprotein (G) was replaced with the LASV glycoprotein complex (GPC). Earlier studies showed that this vaccine (VSVΔG-LASV-GPC) was efficacious in macaques, thus we regenerated VSVΔG-LASV-GPC using laboratory and documentation practices required to support vaccine manufacturing and human trials. The efficacy of the clinical vaccine candidate was assessed in cynomolgus macaques and more extensive immunologic analysis was performed than previously to investigate immune responses associated with protection.

findingsA single VSVΔG-LASV-GPC vaccination elicited innate, humoural and cellular immune responses, prevented development of substantial LASV viraemia, and protected animals from disease. Vaccinated macaques developed polyfunctional antibodies and serum was shown to neutralize virus expressing GPCs representative of geographically diverse LASV lineages.

interpretationThe VSVΔG-LASV-GPC clinical candidate elicited immunity that protected 10 of 10 vaccinated macaques from disease supporting its use in a clinical development program, which recently progressed to phase 2 clinical trials. Moreover, immunologic analysis showed that virus-neutralizing serum antibodies likely played a role in preventing LASV disease in vaccinated macaques.

fundingThis work was supported by the Coalition for Epidemic Preparedness Innovations (CEPI), The National Institute of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH), The Bill and Melinda Gates Global Vaccine Accelerator Program, the Burroughs Wellcome Fund, and financial gifts and support by Nancy Zimmerman, Mark and Lisa Schwartz, and Terry and Susan Ragon.

Indexed as

Lassa FeverLassa virusVesiculovirusViral VaccinesAnimalsAntibodies, NeutralizingAntibodies, ViralClinical Trials as TopicDisease Models, AnimalGenetic VectorsHumansMacaca fascicularisVaccinationVirus ReplicationAntibodies, NeutralizingAntibodies, ViralViral VaccinesClinical vaccine candidateLassa virusNeutralizing antibodiesVesicular stomatitis virus vector

Identifiers

PMID40157130
PMCPMC11994357

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.